advanced and recurrent colorectal cancer
Conditions
Interventions
1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous injection o
Sponsors
Kochi Health Sciences Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Pathologically proved colorectal cancer 2)Age at registration is above 20 3)ECOG Performance status is 0 or 1 4)FOLFOX in treatment(or at least SD)but problems such as continuous infusion of impossible to continue treating patients, Identified as difficult cases at the request of the patient continuous infusion 5)Intake of normal diet and oral drugs is possible 6)With advanced or recurrent measurable disease,colon or rectal cancer 7)At least two cycles or XELOX(+bevacizumab)treatment for possible 8)Written informed consent is taken
Exclusion criteria
Exclusion criteria: 1)severe renal failure 2)severe hypersensitivity to have a history fluorouracil,lebohorinatokarushiumu, platinum, bevacizumab 3)activity with multiple cancers(After which no more than five years of activity) 4)brain metastases(only when using bevacizumab) 5)FOLFOX(+bevacizumab)treatment for 3 or more months after 6)In addition, if deemed unsuitable to participate in this study is the responsible physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FOLFOX(+bevacizumab) from PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| safety,cycle number of XELOX,Quolity of life(FACT-C) | — |
Countries
Japan
Contacts
Public ContactAkihito Tsuji
Kochi Health Sciences Center Department of Medical Oncology
Outcome results
None listed